Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876070 · ClinicalTrials.gov registry record
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 198
- Enrollment target
NCT00876070: Completed study, sponsored by SCRI Development Innovations.
NCT00876070 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 198 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00876070 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 198 participants
- Enrollment target
Study Summary
This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-02 |
What the finished NCT00876070 record still lists
NCT00876070 is an observational study that tracks outcomes without assigning an intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00876070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00876070 about?
NCT00876070 is a clinical study titled "Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer". This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-lin...
What is the current status of trial NCT00876070?
This trial is currently completed. The enrollment target is 198 participants. The study started on 2008-11. Estimated completion is 2011-02.
Who is sponsoring clinical trial NCT00876070?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia